Navigation Links
Late Breaking Data Released at ADA Showed that the Investigational,Use of Januvia and Metformin as Initial Combination Therapy,Provided Significant Glucose Lowering Efficacy over 54 Weeks in,Patients with Type 2 Diabetes

gar control," said John Amatruda, M.D., vice president, clinical research, Merck & Co., Inc. "This study examines the clinical effect of initial combination therapy with JANUVIA and metformin, the two drugs comprising JANUMET, over one year."

An important predictive factor of the magnitude of A1C reduction in response to anti-hyperglycemic therapy is a patient's starting level of A1C. In a subgroup analysis of patients grouped by severity of starting baseline A1C, treatment with JANUVIA 50 mg/metformin 1000 mg twice daily demonstrated increasing mean A1C reductions from baseline the higher the baseline A1C. A mean reduction of 3.1 percent was seen in patients with baseline A1C of 10 percent or more (n=17), while reductions of 2.2 percent, 1.7 percent, and 1.0 percent were seen with baseline A1C values of nine to 10 percent, eight to nine percent, and less than eight percent, respectively.

Investigational study showed JANUVIA significantly improved blood sugar control when added to sulfonylurea or to sulfonylurea and metformin vs. sulfonylurea or sulfonylurea and metformin alone (Poster #535-P; Study #035)

In this study, which was designed to examine the efficacy and safety of JANUVIA in patients with type 2 diabetes whose blood glucose levels were inadequately controlled (A1C levels of 7.5 percent to 10.5 percent) on a sulfonylurea (glimepiride) alone or on a sulfonylurea (glimepiride) plus metformin, JANUVIA demonstrated a significant mean difference from placebo in A1C of 0.9 percent in patients on glimepiride and metformin and 0.6 percent in patients on glimepiride alone (p less than 0.001 for both comparisons to the addition of placebo).

After a titration/stabilization period on glimepiride (at least 4 mg/day) with or without metformin (at least 1500 mg/day) and a 2-week placebo run-in, 441 patients with a mean baseline A1C of 8.3 percent were randomized to the addition of JANUVIA 100 mg once-daily or placebo for 24 weeks. Of thes
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32

Related medicine technology :

1. VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions
2. Pilot Phase 3 Results of NovaCardias KW-3902 for Acute Congestive Heart Failure Presented at Late-Breaking Session of Heart Failure Congress 2007
3. Breaking Multi-Center Study: Masimo SET Pulse Oximetry Technology Shown to Significantly Lower Instances of Severe Retinopathy of Prematurity in Extremely Low Birth Weight Infants
4. Bentley Late Breaking Abstract Accepted for Poster Presentation at American Diabetes Association Scientific Sessions
5. Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR Annual Meeting Late-Breaking Clinical Trials Session
6. Everest Data on Short- and Long-Term Use of Otsukas Investigational Novel Treatment, Tolvaptan, Published in Journal of the American Medical Association and Featured in ACCs Late Breaking Clinical Trials
7. Lupus Foundation of America Statement on Results for Clinical Study of CellCept Released by Aspreva Pharmaceutical Company
8. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
9. Amlodipine and Olmesartan Study Results Released;Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
10. Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
11. New Anti-Rejection Medication 6-Month Results for Heart Transplant Recipients to Be Released at International Heart and Lung Transplant Meeting
Post Your Comments:
(Date:5/24/2013)... 24, 2013 The potential of ... delivery of therapeutic agents has been receiving undeniable attention ... showing significant promise. The crucial formulation considerations for orally ... play a major role in the efficiency of pulmonary ... development of new formulation techniques and devices in recent ...
(Date:5/23/2013)... y PARÍS, 24 de mayo de ... ), un destacado desarrollador y fabricante de herramientas ... la diagnosis y tratamiento de la enfermedad vascular ... del ensayo ADVISE ( Ad enosine V ... E valuation) II durante la sesión de ensayo ...
(Date:5/23/2013)... , May 23, 2013 Nephros, Inc. (OTC ... medical device company that develops and sells high performance ... its rights offering.  In addition, the concurrent temporary reduction ... expired on May 17, 2013. Nephros estimates ... from the rights offering.   A portion of the proceeds ...
Breaking Medicine Technology:Inhalaltion Drug Delivery: 11-12 September - Berlin, Germany 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 2Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 3Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 4Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 5Volcano anuncia los resultados preliminares del estudio ADVISE II y su inclusión en el ensayo SYNTAX2 6Nephros Announces Completion of Rights Offering 2Nephros Announces Completion of Rights Offering 3Nephros Announces Completion of Rights Offering 4
... SILVER SPRING, Md., May 9, 2011 /PRNewswire-USNewswire/ – CoMeD ... a Republican State Senator filed an amendment to regulate ... made it illegal to buy, sell, manufacture, deliver, import, ... 0.3 micrograms of organic or inorganic mercury per milliliter ...
... May 9, 2011 TriReme Medical, Inc. (TriReme), a ... treatment of complex vascular disease, announced today the appointment ... their Board of Directors. Mr. Bose, Founder ... Singapore and was until recently Company Group Chairman at ...
Cached Medicine Technology:Florida Legislature Refuses to Limit Mercury in Vaccines 2Florida Legislature Refuses to Limit Mercury in Vaccines 3TriReme Medical Lines Up Asian Strategy With Key Appointment of New Board Members 2
(Date:5/24/2013)... of five medical students have an unconscious bias against ... authors, from Wake Forest Baptist Medical Center, noted the ... of obesity. They concluded that teaching medical students to ... the millions of Americans who are overweight or obese. ... relationship, and even a patient,s willingness or desire to ...
(Date:5/24/2013)... fractional flow reserve (FFR) using pressure wire assessment ... leads to significant changes in the management of ... a study reported at EuroPCR 2013. , The ... strategy at coronary angiography for diagnosis of chest ... assessment of FFR in all the main coronary ...
(Date:5/24/2013)... Transcatheter aortic valve implantation (TAVI) is effective and safe ... first results from a multicentre Asian registry reported at ... become a treatment option for selected patients with symptomatic ... from North American or European centres," Paul Chiam, senior ... the conference. He explained that it is unknown whether ...
(Date:5/24/2013)... A new discovery at Oregon Health & Science University ... reacts when infected with the highly evasive HIV virus ... been utilizing this unique approach to develop its own ... results in animal studies. This latest research finding will ... the journal Science . , "A major ...
(Date:5/24/2013)... 24, 2013 The producers of Health ... for Charlotte, North Carolina. It is one of the largest ... companies. The city is populated with more than a million ... residents in both North and South Carolina. Viewers who are ... can tune into WAXN-TV 64 Eyewitness News during the month ...
Breaking Medicine News(10 mins):Health News:Many Medical Students Have Anti-Fat Bias, Study Finds 2Health News:Diagnostic coronary angiography: Functional flow reserve changes decisions in 25 percent of cases 2Health News:Registry confirms TAVI efficacy and safety in Asian patients 2Health News:OHSU research highlights promising strategy to help vaccines outsmart HIV 2Health News:Health Briefs TV Presents May Air Dates for Charlotte, North Carolina 2
... rankings aim to help families choose best option , , ... Medicare and Medicaid Services unveiled an updated Web site ... for elderly Americans and their families. , The updated ... similar to that used for hotels and motels, to ...
... NY, December 18, 2008Medical acupuncture, which is acupuncture performed ... school, is being used increasingly for pain control. Richard ... , a peer-reviewed journal ( www.liebertpub.com/acu ) and the ... is at the forefront of these efforts in the ...
... the European Association of Urology (EAU) will be held from ... (SE). The scientific programme covers the whole range of the ... it will all be discussed at the congress. ... are extended to a full-day event called EAU International Day ...
... study,s design may be to blame for desmoteplase,s poor showing, ... experimental clot-busting drug derived from the saliva of the vampire ... trial. , But hope for the drug, called desmoteplase, remains ... large enough to provide clear results. , "The sample size ...
... who suffer from thinning hair and hair loss with an all-natural ... all-natural DHT blockers with no side effects. , ... ... offering patients who suffer from thinning hair and hair loss with ...
... drug eluting stents (DES) stents coated with medication to ... angioplasty had better outcomes one year later than patients with ... published in CMAJ http://www.cmaj.ca/press/080050.pdf . , Mortality ... stents was significantly lower than for those with bare metal ...
Cached Medicine News:Health News:Government Launches Nursing Home Rating System 2Health News:Government Launches Nursing Home Rating System 3Health News:Annual Congress European Association of Urology: highlights in Stockholm 2Health News:Bat Saliva-Based Stroke Drug Disappoints in Trial 2Health News:Bat Saliva-Based Stroke Drug Disappoints in Trial 3Health News:Your Chemist Shop Offers Patients a Revolutionary Alternative to Other Hair Loss Treatments for Both Men and Women 2
The 7700 Reciprocating Saw completes the large power system with our simple twist-lock blade hub and selection of saw blades....
The 7500 Drill/Reamer operates at two speeds for multiple applications, which is automatically controlled by the 16 different coupler attachments. The drill reamer can be used for, but is not limited...
... SmartDriver System consists of a pistol-grip handpiece ... with a wide range of couplers that ... orthopedic surgical applications., ,The Battery SmartDriver ... compared to the original Battery SmartDriver. The ...
... Meniscus Implant (CMI) is a type I ... irreparable meniscus tear or loss of meniscus ... procedure. The purpose of the CMI ... and return to a more vigorous lifestyle, ...
Medicine Products: